본문 바로가기
KERD
논문KCI 등재

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

Eunjoo Choi|Francis Sahngun Nahm|Pyung-Bok Lee|Grisuna Singh|Sejin Song
대한통증학회 (The Korean Pain Society)|2020.07|The Korean Journal of Pain|제33권 제3호|pp. 201-207|DOI 10.3344/kjp.2020.33.3.201

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

PainImmunityHerpes ZosterNeuralgiaVaccinesPostherpeticHerpes Zoster VaccineHumoralAttenuatedSubunitSynthetic.

초록

Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines

Abstract

Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines

참고문헌 (43)

  1. Young Hoon Jeon, "Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment", The Korean Journal of Pain, 28(3), pp.177~184 (2015), 대한통증학회
  2. Gilden DH, "Neurologic complications of the reactivation of varicella-zoster virus", N Engl J Med, 342, pp.635~645 (2000)
  3. Johnson RW, "Clinical practice. Postherpetic neuralgia", N Engl J Med, 371, pp.1526~1533 (2014)
  4. Gershon AA, "Varicella zoster virus infection", Nat Rev Dis Primers, 1, pp.15016~ (2015)
  5. Meera Shrestha, "Modalities in managing postherpetic neuralgia", The Korean Journal of Pain, 31(4), pp.235~243 (2018), 대한통증학회
  6. Leung J, "Herpes zoster incidence among insured persons in the United States, 1993-2006 : evaluation of impact of varicella vaccination", Clin Infect Dis, 52, pp.332~340 (2011)
  7. Ivan Chernev, "Herpes Zoster and Diabetes Mellitus", The Korean Journal of Pain, 27(1), pp.92~92 (2014), 대한통증학회
  8. Kimberlin DW, "Varicella-zoster vaccine for the prevention of herpes zoster", N Engl J Med, 356, pp.1338~1343 (2007)
  9. Hong MJ, "Epidemiology of postherpetic neuralgia in Korea : an electronic population health insurance system based study", Medicine (Baltimore), 95, pp.e3304~ (2016)
  10. 김경훈, "Herpes Zoster Vaccination", The Korean Journal of Pain, 26(3), pp.242~248 (2013), 대한통증학회
  11. Cunningham AL, "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older", N Engl J Med, 375, pp.1019~1032 (2016)
  12. Weller TH, "The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro", J Exp Med, 108, pp.843~868 (1958)
  13. Takahashi M, "Live vaccine used to prevent the spread of varicella in children in hospital", Lancet, 2, pp.1288~1290 (1974)
  14. Wang L, "Efficacy of varicella(VZV)vaccination : an update for the clinician", Ther Adv Vaccines, 4, pp.20~31 (2016)
  15. Sanford M, "Zoster vaccine(Zostavax) : a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults", Drugs Aging, 27, pp.159~176 (2010)
  16. Syed YY, "Recombinant zoster vaccine(Shingrix®) : a review in herpes zoster", Drugs Aging, 35, pp.1031~1040 (2018)
  17. Dagnew AF, "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies : a phase 3, randomised, clinical trial and posthoc efficacy analysis", Lancet Infect Dis, 19, pp.988~1000 (2019)
  18. Warrington R, "Summary of the NACI update on herpes zoster vaccines", Can Commun Dis Rep, 44, pp.220~225 (2018)
  19. Mullane KM, "Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies : a two-arm, randomised, double-blind, phase 3 trial", Lancet Infect Dis, 19, pp.1001~1012 (2019)
  20. Eberhardson M, "Safety and immunogenicity of inactivated varicellazoster virus vaccine in adults with autoimmune disease : a phase 2, randomized, double-blind, placebo-controlled clinical trial", Clin Infect Dis, 65, pp.1174~1182 (2017)
  21. Parrino J, "Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies", Vaccine, 35, pp.1764~1769 (2017)
  22. Cohen JI, "Strategies for herpes zoster vaccination of immunocompromised patients", J Infect Dis, 197(Suppl 2), pp.S237~241 (2008)
  23. Lecrenier N, "Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention", Expert Rev Vaccines, 17, pp.619~634 (2018)
  24. Choi WS, "Herpes zoster vaccine in Korea", Clin Exp Vaccine Res, 2, pp.92~96 (2013)
  25. Schmader KE, "Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years", Clin Infect Dis, 54, pp.922~928 (2012)
  26. Oxman MN, "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults", N Engl J Med, 352, pp.2271~2284 (2005)
  27. Schmader KE, "Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy", Clin Infect Dis, 55, pp.1320~1328 (2012)
  28. Morrison VA, "Long-term persistence of zoster vaccine efficacy", Clin Infect Dis, 60, pp.900~909 (2015)
  29. Tseng HF, "Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years", J Infect Dis, 213, pp.1872~1875 (2016)
  30. Baxter R, "Long-term effectiveness of the live zoster vaccine in preventing shingles : a cohort study", Am J Epidemiol, 187, pp.161~169 (2018)
  31. Zussman J, "Zoster vaccine live for the prevention of shingles in the elderly patient", Clin Interv Aging, 3, pp.241~250 (2008)
  32. Didierlaurent AM, "Adjuvant system AS01 : helping to overcome the challenges of modern vaccines", Expert Rev Vaccines, 16, pp.55~63 (2017)
  33. Berarducci B, "Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection", J Virol, 80, pp.9481~9496 (2006)
  34. Symoniak MR, "Herpes zos-ter subunit vaccine for the prevention of herpes zoster", Am J Health Syst Pharm, 75, pp.861~869 (2018)
  35. Lal H, "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults", N Engl J Med, 372, pp.2087~2096 (2015)
  36. Schwarz TF, "Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults", Hum Vaccin Immunother, 14, pp.1370~1377 (2018)
  37. López-Fauqued M, "Safety profile of the adjuvanted recombinant zoster vaccine : pooled analysis of two large randomised phase 3 trials", Vaccine, 37, pp.2482~2493 (2019)
  38. McGirr A, "The comparative efficacy and safety of herpes zoster vaccines : a network meta-analysis", Vaccine, 37, pp.2896~2909 (2019)
  39. Grupping K, "Immunogenicity and safety of the HZ", su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine, 2017, pp.216, 1343~1351
  40. Dooling KL, "Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines", MMWR Morb Mortal Wkly Rep, 67, pp.103~108 (2018)
  41. German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI), "Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany:statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI)", Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 60, pp.1162~1179 (2017)
  42. Siedler A, "Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine : statement of the German Standing Committee on Vaccination(STIKO)at the Robert Koch Institute", Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 62, pp.352~376 (2019)
  43. Gabutti G, "Varicella zoster virus vaccines : an update", Immunotargets Ther, 8, pp.15~28 (2019)

이 간행물의 다른 논문 (12건)

The interpretation bias and trap of multicenter clinical researchDaehyun Jopp. 199-200Zoster sine herpete: a reviewJuan Li, Lulin Ma, Song Cao, Junli Zhoupp. 208-215Exploring the role and mechanisms of diallyl trisulfide and diallyl disulfide in chronic constriction-induced neuropathic pain in ratsChunfeng Wang, Ying Liu, Jianzhong Huang, Gang Wang, Yan Yang, Hao Wang, Xiao Wangpp. 216-225Comparison of treatment outcomes in lumbar central stenosis patients treated with epidural steroid injections: interlaminar versus bilateral transforaminal approachIpek Saadet Edipoglu, Osman Hakan Gunduz, Savas Sencan, Gunay Yolcu, Alp Eren Celenlioglupp. 226-233Patients’ perception about opioids and addiction in South KoreaSung Jun Hong, Jung Eun Kim, Yun Hee Lim, Jae Hun Jeong, Hey Ran Choi, Sun Kyung Park, Jae Hun Kim, Cho Long Kim, Ho Sik Moon, Hakjong Youpp. 234-244
원문 보기